---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-016002"
form_type: "8-K"
ticker: "IBO"
cik: "0001834105"
company_name: "IMPACT BIOMEDICAL INC."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-19T00:04:42.904312+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Impact BioMedical announces reverse merger with Dr Ashleys; shareholders to receive 4.80% of combined entity

## Summary
- Impact BioMedical (IBO) will merge with Dr Ashleys via a reverse merger; existing Impact shareholders receive 4.80% of the new PubCo's ordinary shares.
- Dr Ashleys shareholders get 94.20% of PubCo; Dr Ashleys management will control the combined company's board and operations.
- 86.81% of Impact's shareholders (by as-converted shares) have signed a voting agreement to approve the deal.
- Closing conditions include Impact having at least $10,000 net cash and zero net debt, and NYSE American listing approval.
- The combined entity will be renamed Dr Ashleys Limited and continue trading on NYSE American under a new name.

## SEC filing metadata
- accession: 0001641172-25-016002
- form_type: 8-K
- ticker: IBO
- cik: 0001834105
- company_name: IMPACT BIOMEDICAL INC.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1834105/000164117225016002/0001641172-25-016002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1834105/000164117225016002/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-016002
- JSON: https://secwatch.observer/filing/0001641172-25-016002.json
- Plain text: https://secwatch.observer/filing/0001641172-25-016002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.